F182112
Phase 2Small molecule
F182112 is one of 18 small molecule programs targeting Systemic Lupus Erythematosus (SLE). It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
9 competitors in Multiple Myeloma (MM)
#DrugCompanyPhaseTrials
1Tecvayli
Johnson & JohnsonPhase 3
TALVEY
Johnson & JohnsonPhase 3
Darzalex
Johnson & JohnsonPhase 3
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Actemra
RochePhase 2
Elranatamab
PfizerPhase 2
CM336
KKeymed Biosciences Co.Ltd
Phase 2
F182112
SShandong New Time Pharmaceutical Co., LTD
Phase 2
Qls4131
IInstitute of Hematology & Blood Diseases Hospital, China
Phase 2
Beqalzi
BBeOne Medicines
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma1 trial
Multiple Myeloma (MM)1 trial
Safety and Efficacy of F182112 in Combination With Isatuximab and Lenalidomide in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: A Prospective, Single-Arm, Exploratory Clinical Study
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07828522·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F182112. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details